ERBB2 and breast carcinoma: In accordance with previous studies, focusing on breast cancer patients with molecular subtypes luminal A and B, basal, and HER2+ [5], we extended the link of CDK8 expression to overall survival to a selected TNBC patient cohort (Fig. 6B).